Fulgent Genetics Valuation
| FLGT Stock | USD 22.97 0.09 0.39% |
At this time, the firm appears to be undervalued. Fulgent Genetics shows a prevailing Real Value of $29.32 per share. The current price of the firm is $22.97. Our model computes the value of Fulgent Genetics from reviewing the firm fundamentals such as Profit Margin of (0.14) %, current valuation of 341.18 M, and Shares Outstanding of 30.91 M as well as analyzing its technical indicators and probability of bankruptcy.
Price Book 0.6301 | Enterprise Value | Enterprise Value Ebitda (4.34) | Price Sales 2.2483 | Forward PE 7.9365 |
Undervalued
Today
Please note that Fulgent Genetics' price fluctuation is very steady at this time. Calculation of the real value of Fulgent Genetics is based on 3 months time horizon. Increasing Fulgent Genetics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Fulgent Genetics' intrinsic value may or may not be the same as its current market price of 22.97, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 22.97 | Real 29.32 | Target 33.67 | Hype 23.0 |
The intrinsic value of Fulgent Genetics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Fulgent Genetics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Fulgent Genetics helps investors to forecast how Fulgent stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Fulgent Genetics more accurately as focusing exclusively on Fulgent Genetics' fundamentals will not take into account other important factors: Fulgent Genetics Cash |
|
Fulgent Genetics Total Value Analysis
Fulgent Genetics is currently forecasted to have valuation of 341.18 M with market capitalization of 709.44 M, debt of 8.47 M, and cash on hands of 515.4 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Fulgent Genetics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
341.18 M | 709.44 M | 8.47 M | 515.4 M |
Fulgent Genetics Investor Information
About 33.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.63. Some equities with similar Price to Book (P/B) outperform the market in the long run. Fulgent Genetics has Price/Earnings To Growth (PEG) ratio of 1.32. The entity recorded a loss per share of 1.4. The firm had not issued any dividends in recent years. Based on the key indicators related to Fulgent Genetics' liquidity, profitability, solvency, and operating efficiency, Fulgent Genetics may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter.Fulgent Genetics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Fulgent Genetics has an asset utilization ratio of 23.24 percent. This implies that the Company is making $0.23 for each dollar of assets. An increasing asset utilization means that Fulgent Genetics is more efficient with each dollar of assets it utilizes for everyday operations.Fulgent Genetics Profitability Analysis
Based on Fulgent Genetics' profitability indicators, Fulgent Genetics may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in March. Profitability indicators assess Fulgent Genetics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2015-03-31 | Previous Quarter -19 M | Current Value -6.6 M | Quarterly Volatility 57 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.42 | 0.34 |
|
|
For Fulgent Genetics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Fulgent Genetics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Fulgent Genetics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Fulgent Genetics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Fulgent Genetics over time as well as its relative position and ranking within its peers.
Fulgent Genetics Earnings per Share Projection vs Actual
The next projected EPS of Fulgent Genetics is estimated to be -0.1144 with future projections ranging from a low of -0.19 to a high of -0.0233. Fulgent Genetics' most recent 12-month trailing earnings per share (EPS TTM) is at -1.4. Please be aware that the consensus of earnings estimates for Fulgent Genetics is based on EPS before non-recurring items and includes expenses related to employee stock options.Fulgent Genetics Earnings Estimation Breakdown
The calculation of Fulgent Genetics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Fulgent Genetics is estimated to be -0.1144 with the future projection ranging from a low of -0.19 to a high of -0.0233. Please be aware that this consensus of annual earnings estimates for Fulgent Genetics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.19 Lowest | Expected EPS | -0.02 Highest |
Fulgent Genetics Earnings Projection Consensus
Suppose the current estimates of Fulgent Genetics' value are higher than the current market price of the Fulgent Genetics stock. In this case, investors may conclude that Fulgent Genetics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Fulgent Genetics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 3 | 44.16% | 0.0 | -0.1144 | -1.4 |
Fulgent Genetics Ownership Allocation
Fulgent Genetics holds a total of 30.91 Million outstanding shares. Over half of Fulgent Genetics' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Fulgent Genetics Profitability Analysis
The company reported the previous year's revenue of 283.47 M. Net Loss for the year was (43.82 M) with profit before overhead, payroll, taxes, and interest of 130.14 M.About Fulgent Genetics Valuation
The stock valuation mechanism determines Fulgent Genetics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Fulgent Genetics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Fulgent Genetics. We calculate exposure to Fulgent Genetics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Fulgent Genetics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 123.3 M | 174.3 M | |
| Pretax Profit Margin | (0.18) | (0.16) | |
| Operating Profit Margin | (0.23) | (0.22) | |
| Net Loss | (0.15) | (0.14) | |
| Gross Profit Margin | 0.34 | 0.42 |
Fulgent Genetics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Fulgent Genetics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 30.2 M | |
| Quarterly Earnings Growth Y O Y | -0.986 | |
| Forward Price Earnings | 7.9365 |
Fulgent Genetics Current Valuation Indicators
Fulgent Genetics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Fulgent Genetics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Fulgent Genetics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Fulgent Genetics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Fulgent Genetics' worth.Additional Tools for Fulgent Stock Analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.